Test Product HY07121

Phase 2Small molecule

SSichuan Huiyu Pharmaceutical Co., Ltd

Test Product HY07121 is one of 73 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsRecruiting

Patients With Advanced Solid TumorsRecruiting

Tyrosine Kinase InhibitorsRecruiting

Advanced Solid TumorsPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Tyrosine Kinase InhibitorsPreclinical

Recruiting

Competition

Competitive Landscape

286 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

18 2

Paraplatin

AAvyxa

Phase 2

31 3

Yervoy

Bristol-Myers Squibb

Phase 2

6 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

18 5

Erbitux

IImclone

Phase 2

14 6

Tuoyi

CCoherus Oncology, Inc.

Phase 2

6 7

Trifluridine/tipiracil

AbbVie

Phase 2

2 8

Standard Chemotherapy

Roche

Phase 2

1 9

BNT327

BioNTech

Phase 2

1 10

IL-2

FFate Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT06243354

Q3 2027

Phase 1/2Recruiting

Advanced Solid Tumors

NCT07069062

Q4 2027

PreclinicalRecruiting

Study completion

NCT06639256

Q2 2028

PreclinicalRecruiting

Study completion

NCT06712680

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

Recruiting·SSichuan Huiyu Pharmaceutical Co., Ltd·Phase 1/2·NCT06243354·257 enrolled

Advanced Solid Tumors1 trial

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors

Recruiting·SSichuan Huiyu Pharmaceutical Co., Ltd·Phase 1/2·NCT07069062·261 enrolled

Unspecified2 trials

A Phase I/II , Open-label, Multi-center, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HYP-6589 Monotherapy in Advanced Solid Tumors and Combination With Tyrosine Kinase Inhibitors in Patients With Advanced NSCLC With Target-driven Gene Positivity

Recruiting·SSichuan Huiyu Pharmaceutical Co., Ltd·Preclinical·NCT06712680·115 enrolled

An Open-label, Multiple-center, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

Recruiting·SSichuan Huiyu Pharmaceutical Co., Ltd·Preclinical·NCT06639256·258 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Test Product HY07121. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Test Product HY07121 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Test Product HY07121. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Huiyu Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Huiyu Pharmaceutical Co., Ltd

Test Product HY07121

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Advanced Solid Tumors1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News